SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1765-1772. Prepublished online as a Blood First Edition Paper on October 17, 2006; DOI 10.1182/blood-2006-05-022335. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-05-022335v1 109/4/1765    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Scott Baker, K. Articles by Bhatia, S. Search for Related Content PubMed PubMed Citation Articles by Scott Baker, K. Articles by Bhatia, S. Related Collections Transplantation Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study K. Scott Baker1, Kirsten K. Ness1, Julia Steinberger1, Andrea Carter2, Liton Francisco2, Linda J. Burns1, Charles Sklar3, Stephen Forman4, Daniel Weisdorf1, James G. Gurney5, and Smita Bhatia2,4 1 Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis; 2 Division of Populations Sciences, City of Hope National Medical Center, Duarte, CA; 3 Memorial Sloan-Kettering Cancer Center, Department of Pediatrics, New York, NY; 4 Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; and 5 Department of Pediatrics, University of Michigan, Ann Arbor We ascertained the prevalence of self-reported late occurrence of diabetes, hypertension, and cardiovascular (CV) disease in 1089 hematopoietic cell transplantation (HCT) survivors who underwent HCT between 1974 and 1998, survived at least 2 years, and were not currently taking immunosuppressant agents and compared them with 383 sibling controls. All subjects completed a 255-item health questionnaire. The mean age at survey completion was 39.3 years for survivors and 38.6 years for siblings; mean follow-up was 8.6 years. Adjusting for age, sex, race, and body mass index (BMI), survivors of allogeneic HCT were 3.65 times (95% confidence interval [CI], 1.82-7.32) more likely to report diabetes than siblings and 2.06 times (95% CI, 1.39-3.04) more likely to report hypertension compared with siblings but did not report other CV outcomes with any greater frequency. Recipients of autologous HCTs were no more likely than siblings to report any of the outcomes studied. Allogeneic HCT survivors were also more likely to develop hypertension (odds ratio [OR] = 2.31; 95% CI, 1.45-3.67) than autologous recipients. Total body irradiation (TBI) exposure was associated with an increased risk of diabetes (OR = 3.42; 95% CI, 1.55-7.52). Thus, HCT survivors have a higher age- and BMI-adjusted risk of diabetes and hypertension, potentially leading to a higher than expected risk of CV events with age. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Tichelli, C. Bucher, A. Rovo, G. Stussi, M. Stern, M. Paulussen, J. Halter, S. Meyer-Monard, D. Heim, D. A. Tsakiris, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation Blood, November 1, 2007; 110(9): 3463 - 3471. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020